Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
BioNexus Gene Lab Corp. (NASDAQ: BGLC)
BGLC Stock Predictions and Ratings
WSX Rating:
SELL
WSX Forecast (1yr):
-5%
Analyst Rating:
NOT AVAILABLE
Analyst Forecast (1yr):
NOT AVAILABLE
BGLC Stock Analysis
BGLC
PE Ratio:
BGLC
PEG Ratio:
Not Available
BGLC
Forward EPS Growth (12 month):
0.00%
BGLC
PS Ratio:
0.8
BGLC
PSG Ratio:
Not Available
BGLC
Forward Revenue Growth (12 month):
0.00%
BGLC Articles
No data was found